[Skip to Navigation]
Sign In
JAMA Network Clinical Guideline Synopsis
January 13, 2021

American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer

Author Affiliations
  • 1Ramsay Sime Darby Healthcare, Malaysia
  • 2University Malaya, Kuala Lumpur, Malaysia
  • 3Breast Surgery Section, International Center for the Study of Breast Cancer Subtypes, Weill Cornell Medicine, New York, New York
JAMA Surg. 2021;156(3):284-285. doi:10.1001/jamasurg.2020.6254

Lifetime risk of breast cancer for high-penetrance genes, such as BRCA1/2, is approximately 70%, while the lifetime risk of the moderate-penetrance genes ranges from 35% to 60% for PALB2 and 25% to 30% for ATM and truncating CHEK2 mutations.1 While there are many guidelines on risk management, there are few guidelines on the role of local or systemic treatment in women with hereditary breast cancer. This joint guideline offers recommendations for the management of breast cancer in patients with germline mutations in BRCA1/2 PALB2, CHEK2, TP53, and ATM.2

Add or change institution